Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | LSS | P48449 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9834919 | 0.98 | HRH3 (0.50) | HRH3LSSALDH1A1POLBMAPT | |
| SCHEMBL25137173 | 0.83 | HRH3 (0.56) | HRH3LSSALDH1A1MAPTTSHR | |
| SCHEMBL12734915 | 0.81 | PYCR1 (0.62) | HRH3LSSALDH1A1POLBMAPT | |
| SCHEMBL65825 | 0.81 | ALDH1A1 (0.59) | HRH3LSSALDH1A1POLBMAPT | |
| SCHEMBL31556890 | 0.80 | HRH3 (0.56) | HRH3ALDH1A1MAPTHDAC6MCHR1 | |
| SCHEMBL5393101 | 0.80 | HDAC8 (0.64) | HRH3ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL2913661 | 0.79 | HRH3 (0.52) | HRH3LSSALDH1A1TSHRHDAC6 | |
| Trimethylammonium SCHEMBL19042854 | 0.79 | CA1 (0.55) | ALDH1A1POLBMAPTSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL5065552 | 0.79 | ALDH1A1 (0.57) | HRH3LSSALDH1A1POLBMAPT | |
| SCHEMBL7159528 | 0.79 | ALDH1A1 (0.57) | HRH3LSSALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104689809-B | Preparation and application of positive charge type polysaccharide derivative chiral stationary phase | 台州学院 | 2017-04-26 | — | — | CN | claimed |
| CN-104689809-A | Preparation and application of positive charge type polysaccharide derivative chiral stationary phase | UNIV TAIZHOU | 2015-06-10 | — | — | CN | claimed |
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-12-30 | — | — | US | disclosed |
| WO-2025073682-A1 | METHOD FOR THE KETONE FUNCTIONALISATION OF POLYETHYLENES AND COPOLYMERS CONTAINING ETHYLENE UNITS AND 1,3-DIENE UNITS | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2025-04-10 | — | — | WO | disclosed |
| CN-115279747-B | FYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| CN-115279747-A | Novel fYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4073057-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2022-10-19 | — | — | EP | disclosed |
| EP-3708562-B1 | METHOD FOR PRODUCING SEMICARBAZIDE COMPOUND | TOKUYAMA CORP (JP) | 2022-08-17 | — | — | EP | disclosed |
| EP-0623592-B1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | VERTEX PHARMA (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5843905-A | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5677283-A | α-heteroaryloxymethyl ketones as interleukin - 1 β converting enzyme inhibitors | SANOFI (FR) | 1997-10-14 | — | — | US | disclosed |
| US-5585357-A | Heteroaryloxymethyl ketones as interleukin-1βconverting enzyme inhibitors | SANOFI WINTHROP INC. (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0644198-A1 | Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | FYN, LCK, LYN | HRH3 2608/4885LSS 3797/4885ALDH1A1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.